Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing
Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing
复制标题
DOI：
10.1093/infdis/jiaa656
复制
发表时间：
2021-02-08
影响因子：
6.4
通讯作者：
Schrezenmeier, Hubert
中科院分区：
文献类型：
--
作者：
Jahrsdoerfer, Bernd;Kroschel, Joris;Schrezenmeier, Hubert
高灵敏度和特异性的抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体检测平台对于评估潜在的SARS-CoV-2恢复期血浆供体，研究SARS-CoV-2感染的传播以及识别血清转化个体变得越来越重要。本研究提供了4种抗SARS-CoV-2平台的比较验证。该研究的一个独特之处是使用了2019年冠状病毒病康复期患者的代表性队列，这些患者的病程为轻度至中度。所有平台均显示出与SARS-CoV-2空斑减少中和试验的显著相关性，其中Euroimmun和Roche平台的灵敏度最高，这表明它们优先用于筛查SARS-CoV-2感染风险增加的人群。
Highly sensitive and specific platforms for the detection of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies are becoming increasingly important for evaluating potential SARS-CoV-2 convalescent plasma donors, studying the spread of SARS-CoV-2 infections, and identifying individuals with seroconversion. This study provides a comparative validation of 4 anti-SARS-CoV-2 platforms. A unique feature of the study is the use of a representative cohort of convalescent patients with coronavirus disease 2019 and a mild to moderate disease course. All platforms showed significant correlations with a SARS-CoV-2 plaque reduction neutralization test, with highest sensitivities for the Euroimmun and the Roche platforms, suggesting their preferential use for screening persons at increased risk of SARS-CoV-2 infections.